Myriad Genetics, Inc.MYGN was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 25% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Myriad Genetics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is positive.
Myriad Genetics, Inc. Price
A better-ranked stock worth considering in the Medical - Biomedical and Genetics space is VIVUS, Inc. VVUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Looking for Ideas with Even Greater Upside?
Most of Zacks' investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report